IL122358A - Stable gel formulation for topical treatment of skin conditions (acne psoriasis) containing active agent and non-aqueous vehicles for control of solubility - Google Patents

Stable gel formulation for topical treatment of skin conditions (acne psoriasis) containing active agent and non-aqueous vehicles for control of solubility

Info

Publication number
IL122358A
IL122358A IL12235895A IL12235895A IL122358A IL 122358 A IL122358 A IL 122358A IL 12235895 A IL12235895 A IL 12235895A IL 12235895 A IL12235895 A IL 12235895A IL 122358 A IL122358 A IL 122358A
Authority
IL
Israel
Prior art keywords
active agent
gel formulation
solubility
skin conditions
stable gel
Prior art date
Application number
IL12235895A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IL122358A publication Critical patent/IL122358A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12235895A 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne psoriasis) containing active agent and non-aqueous vehicles for control of solubility IL122358A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25509494A 1994-06-07 1994-06-07
IL11404995A IL114049A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) containing active agent and non-aqueous vehicles for control or release of active agent from the gel

Publications (1)

Publication Number Publication Date
IL122358A true IL122358A (en) 2001-01-28

Family

ID=22966815

Family Applications (3)

Application Number Title Priority Date Filing Date
IL12235995A IL122359A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) comprising ethyl-6-[2-(4,4)-dimethylthiochroman-6-yl] nicotinate in a pharmaceutical carrier and a method for its preparation
IL11404995A IL114049A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) containing active agent and non-aqueous vehicles for control or release of active agent from the gel
IL12235895A IL122358A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne psoriasis) containing active agent and non-aqueous vehicles for control of solubility

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL12235995A IL122359A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) comprising ethyl-6-[2-(4,4)-dimethylthiochroman-6-yl] nicotinate in a pharmaceutical carrier and a method for its preparation
IL11404995A IL114049A (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions (acne, psoriasis) containing active agent and non-aqueous vehicles for control or release of active agent from the gel

Country Status (13)

Country Link
US (2) US5914334A (de)
EP (2) EP1147778B1 (de)
AT (2) ATE336263T1 (de)
AU (1) AU693905B2 (de)
CA (1) CA2191773C (de)
DE (2) DE69526344T2 (de)
DK (1) DK1147778T3 (de)
ES (2) ES2173958T3 (de)
IL (3) IL122359A (de)
PT (1) PT1147778E (de)
TW (1) TW379143B (de)
WO (1) WO1995033489A1 (de)
ZA (1) ZA954599B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
IT1288708B1 (it) * 1996-10-17 1998-09-23 Achille Sandoli Composizione farmaceutica comprendente trometamina per il trattamento per via topica dell'acne vulgaris.
EP0969847A1 (de) * 1997-02-20 2000-01-12 Allergan Sales, Inc. Tazarotene und carticosteroid enthaltende zusammensetzungen zur behandlung von psoriasis
EP1001770B1 (de) * 1997-06-11 2005-08-24 Allergan, Inc. Tazaroten und uvb-phototherapie zur behandlung von psoriasis
JP2002512638A (ja) * 1998-03-30 2002-04-23 ザ、プロクター、エンド、ギャンブル、カンパニー スキンケア組成物
US20020160995A1 (en) * 1998-08-03 2002-10-31 Easterling W. Jerry Medication and method for remediating existing scars through transdermal, topical delivery of calcium channel blockers
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
JP2003531157A (ja) * 2000-04-26 2003-10-21 ワトソン ファーマシューティカルズ， インコーポレイテッド オキシブチニン治療に関連した有害な経験の最小化
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
CN101491520B (zh) * 2002-05-28 2011-03-16 尼科梅德有限责任公司 局部应用的药物制剂
US20040018220A1 (en) * 2002-07-26 2004-01-29 Chiou Consulting, Inc. Aqueous compositions for facial cosmetics
KR20050085740A (ko) * 2002-12-17 2005-08-29 갈데르마 리써어치 앤드 디벨로프먼트,에스.엔.씨. 염기를 이용하여 용매 내에서 가용화된 레티노이드를화학적으로 안정화시키는 방법
FR2848451B1 (fr) * 2002-12-17 2007-01-12 Galderma Res & Dev Procede de stabilisation chimique d'un retinoide solubilise et composition aqueuse obtenue selon le procede comprenant au moins un retinoide sous forme salifiee
US9173835B2 (en) 2005-05-10 2015-11-03 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
US20070060620A1 (en) * 2005-09-09 2007-03-15 John Sefton Use of RAR retinoid agonists to increase sperm count and sperm mobility in males
US20070077220A1 (en) * 2005-09-30 2007-04-05 Ramirez Jose E Stable ascorbic acid compositions
US20070269534A1 (en) * 2006-02-02 2007-11-22 Ramirez Jose E Methods of treating skin to enhance therapeutic treatment thereof
US20070178058A1 (en) * 2006-02-02 2007-08-02 Ramirez Jose E Methods of using stable ascorbic acid compositions
US9107844B2 (en) * 2006-02-03 2015-08-18 Stiefel Laboratories Inc. Topical skin treating compositions
BRPI0709674A2 (pt) 2006-03-31 2011-12-06 Stiefel Res Australia Pty Ltd gel de suspensão espumante
MXPA06008988A (es) * 2006-08-08 2008-02-07 Fernando Ahumada Ayala Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas).
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
LT2544532T (lt) 2010-03-12 2017-06-12 Monsanto Technology Llc Agrocheminių gelių kompozicijos
CN103249402A (zh) * 2010-10-08 2013-08-14 赫尔普百治疗有限公司 新组合物
CA2929292C (en) 2013-10-31 2021-11-02 Sun Pharmaceutical Industries Limited Topical pharmaceutical composition of acitretin
JP2022506944A (ja) * 2018-11-08 2022-01-17 ヴァーソナ セラピューティクス，インコーポレーテッド ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
KR20230039979A (ko) * 2021-09-15 2023-03-22 서울대학교산학협력단 아토피 피부염 예방 또는 치료용 겔 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934028A (en) * 1974-04-22 1976-01-20 The Regents Of The University Of California Acne and psoriasis treatment with retinoic acid analogs
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4810804A (en) * 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
DE69029804T2 (de) * 1989-06-07 1997-09-04 Gail S Bazzano VEHIKEL MIT LANGSAMER FREISETZUNG ZUR VERMINDERUNG DER HAUTREIZUNG TOPISCHER retinoidhaltiger MITTEL
AU670777B2 (en) * 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
EP1001770B1 (de) * 1997-06-11 2005-08-24 Allergan, Inc. Tazaroten und uvb-phototherapie zur behandlung von psoriasis
US6017938A (en) * 1998-07-28 2000-01-25 Bershad; Susan Short contact treatment for acne
US6114348A (en) * 1999-03-10 2000-09-05 Weber; Paul J. Method of treating warts using tazarotene

Also Published As

Publication number Publication date
ES2173958T3 (es) 2002-11-01
EP0764032B1 (de) 2002-04-10
DE69535184T2 (de) 2007-08-23
DK1147778T3 (da) 2006-12-18
AU2821895A (en) 1996-01-04
DE69526344D1 (de) 2002-05-16
CA2191773A1 (en) 1995-12-14
DE69526344T2 (de) 2002-11-07
EP1147778B1 (de) 2006-08-16
ATE336263T1 (de) 2006-09-15
EP1147778A1 (de) 2001-10-24
US5914334A (en) 1999-06-22
ZA954599B (en) 1996-01-26
US6258830B1 (en) 2001-07-10
IL114049A0 (en) 1995-10-31
AU693905B2 (en) 1998-07-09
PT1147778E (pt) 2006-12-29
CA2191773C (en) 2004-08-10
ES2269296T3 (es) 2007-04-01
IL114049A (en) 2000-08-31
WO1995033489A1 (en) 1995-12-14
DE69535184D1 (de) 2006-09-28
ATE215836T1 (de) 2002-04-15
TW379143B (en) 2000-01-11
IL122359A (en) 2001-08-26
EP0764032A1 (de) 1997-03-26

Similar Documents

Publication Publication Date Title
IL122358A (en) Stable gel formulation for topical treatment of skin conditions (acne psoriasis) containing active agent and non-aqueous vehicles for control of solubility
CA2244887A1 (en) Photoprotective compositions
WO1996012498A3 (en) Dermatological compositions containing benzoyl peroxide and a compound reducing skin irritation
KR970706038A (ko) 모발 제거 방법(method of hair removal)
NZ503340A (en) Treatment for hairy hoof warts (papiliomatous digital dermatitis, or PDD)
CA2262870A1 (en) Liposome-based topical vitamin d formulation
AU3685893A (en) Aqueous gel vehicles for retinoids
ES2168414T3 (es) Formulaciones de retinoides en microesferas porosas de irritacion reducida y estabilidad aumentada.
PT1238660E (pt) Distribuicao sustentada de um agente activo utilizando um sistema implantavel
IL94490A0 (en) Stable,cosmetically acceptable topical gel formulation and method of treatment for acne
EP0303915A3 (en) Retinoids for the treatment of skin damaged by light
DE59510687D1 (de) Mittel gegen hyperreaktive und hypoaktive, defizitäre hautzustände sowie manifeste dermatiden
CA2099188A1 (en) Use of a cosmetic composition
AU5347596A (en) External preparations for treating dermatoses
ES2164434T3 (es) Tratamiento topico de psoriasis que utiliza anticuerpos neutralizantes de il-8.
ES2137125A1 (es) La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.
ES2111102T3 (es) Formulaciones cosmeticas y dermatologicas con un contenido activo en acido cis-urocaninico.
ES2193218T3 (es) Combinacion de sustancias activas contra el acne y los comedones inflamados.
CA2231118A1 (en) Pharmaceutical preparation containing nimesulide for topical use
ATE168004T1 (de) Juckreizstillendes mittel
NZ333443A (en) Method of treating a plant disease comprising applying oxi-fulvic acid an acitve ingredient
CA2126704A1 (en) Dermatological Compositions and Methods for the Treatment of Skin Therewith
IL136342A0 (en) Formulation for topical treatment of skin infections
IL122358A0 (en) Stable gel formulation for topical treatment of skin conditions
RU97107046A (ru) Мазь "аникол" для лечения ран, воспалительных и кожных заболеваний у животных

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired